两代患有晚期肺腺癌且对厄洛替尼有持久反应的从不吸烟者。 - Suppr | 超能文献

Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.

作者信息

Pennell Nathan A, Yin Lihong, Keshtgarpour Mani, Ma Patrick C

机构信息

Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.

出版信息

J Thorac Oncol. 2012 Jul;7(7):1200-1. doi: 10.1097/JTO.0b013e318250ed89.

DOI:10.1097/JTO.0b013e318250ed89

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.两代患有晚期肺腺癌且对厄洛替尼有持久反应的从不吸烟者。

J Thorac Oncol. 2012 Jul;7(7):1200-1. doi: 10.1097/JTO.0b013e318250ed89.

2

Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.比较表皮生长因子受体外显子 19 或 21 突变的非小细胞肺癌患者使用吉非替尼和厄洛替尼治疗的临床结局。

J Thorac Oncol. 2014 Apr;9(4):506-11. doi: 10.1097/JTO.0000000000000095.

3

A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.厄洛替尼单药治疗未经治疗的晚期非小细胞肺癌患者的 II 期临床试验：冈山西肺癌研究组试验 0705。

J Thorac Oncol. 2010 Jan;5(1):99-104. doi: 10.1097/JTO.0b013e3181c20063.

4

First case of A859T epidermal growth factor receptor mutation responding to erlotinib.首例对厄洛替尼有反应的A859T表皮生长因子受体突变病例。

J Thorac Oncol. 2011 Mar;6(3):639-40. doi: 10.1097/JTO.0b013e3182037c0c.

5

A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.一项厄洛替尼作为临床选择的非小细胞肺癌患者一线治疗的 II 期临床试验。

Clin Lung Cancer. 2012 Mar;13(2):129-35. doi: 10.1016/j.cllc.2011.08.004. Epub 2011 Oct 14.

6

Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.吉非替尼治疗失败且获得性T790M突变后对厄洛替尼反应良好的肺腺癌

J Thorac Oncol. 2008 Apr;3(4):451-2. doi: 10.1097/JTO.0b013e318169e32a.

7

A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells.一种用于检测肿瘤细胞数量少的非小细胞肺癌样本中表皮生长因子受体（EGFR）突变的灵敏方法。

J Thorac Oncol. 2008 Nov;3(11):1224-35. doi: 10.1097/JTO.0b013e318189f579.

8

Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib.在先前对吉非替尼有反应的晚期非小细胞肺癌患者中，吉非替尼治疗失败后使用厄洛替尼。

J Thorac Oncol. 2008 Aug;3(8):912-4. doi: 10.1097/JTO.0b013e318180275e.

9

Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.细胞角蛋白 19 片段可预测 EGFR 突变型非小细胞肺癌患者表皮生长因子受体酪氨酸激酶抑制剂的疗效。

J Thorac Oncol. 2013 Jul;8(7):892-8. doi: 10.1097/JTO.0b013e31828c3929.

10

Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib.两名接受厄洛替尼治疗的转移性非小细胞肺癌患者的肺部肿瘤完全病理缓解。

J Thorac Oncol. 2011 Nov;6(11):1946-9. doi: 10.1097/JTO.0b013e31822e71f2.

引用本文的文献

1

Correlation between familial cancer history and epidermal growth factor receptor mutations in Taiwanese never smokers with non-small cell lung cancer: a case-control study.台湾非吸烟非小细胞肺癌患者家族癌症病史与表皮生长因子受体突变的相关性：一项病例对照研究。

J Thorac Dis. 2015 Mar;7(3):281-7. doi: 10.3978/j.issn.2072-1439.2015.02.03.

2

Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations.非吸烟的非小细胞肺癌患者的肺癌家族史及其与携带 EGFR 突变的肿瘤的关系。

Lung Cancer. 2013 Mar;79(3):193-7. doi: 10.1016/j.lungcan.2012.12.002. Epub 2012 Dec 27.